Stock Traders Purchase Large Volume of X4 Pharmaceuticals Put Options (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) saw unusually large options trading on Monday. Investors bought 2,515 put options on the company. This is an increase of approximately 132% compared to the average daily volume of 1,084 put options.

X4 Pharmaceuticals Trading Up 2.8 %

X4 Pharmaceuticals stock opened at $1.12 on Wednesday. The business has a 50-day simple moving average of $1.15 and a two-hundred day simple moving average of $0.93. X4 Pharmaceuticals has a 52-week low of $0.57 and a 52-week high of $2.58. The company has a quick ratio of 5.34, a current ratio of 5.34 and a debt-to-equity ratio of 1.07. The company has a market cap of $188.09 million, a P/E ratio of -1.87 and a beta of 0.48.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.05. Analysts predict that X4 Pharmaceuticals will post -0.47 EPS for the current year.

Insider Buying and Selling

In related news, CFO Adam S. Mostafa sold 27,721 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $1.01, for a total transaction of $27,998.21. Following the transaction, the chief financial officer now owns 52,500 shares in the company, valued at $53,025. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Adam S. Mostafa sold 27,721 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $1.01, for a total value of $27,998.21. Following the completion of the transaction, the chief financial officer now owns 52,500 shares in the company, valued at approximately $53,025. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Paula Ragan sold 49,678 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $0.88, for a total value of $43,716.64. Following the completion of the transaction, the chief executive officer now owns 765,068 shares of the company’s stock, valued at approximately $673,259.84. The disclosure for this sale can be found here. Insiders sold 185,708 shares of company stock valued at $170,428 over the last quarter. 1.08% of the stock is owned by company insiders.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. SG Americas Securities LLC lifted its holdings in X4 Pharmaceuticals by 38.8% in the 4th quarter. SG Americas Securities LLC now owns 47,668 shares of the company’s stock worth $40,000 after purchasing an additional 13,328 shares in the last quarter. Barclays PLC raised its position in shares of X4 Pharmaceuticals by 334.8% during the third quarter. Barclays PLC now owns 382,134 shares of the company’s stock valued at $417,000 after buying an additional 294,255 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of X4 Pharmaceuticals in the third quarter worth $678,000. Stonepine Capital Management LLC grew its stake in X4 Pharmaceuticals by 14.5% during the third quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company’s stock valued at $5,748,000 after acquiring an additional 668,422 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. grew its stake in X4 Pharmaceuticals by 76.0% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock valued at $2,913,000 after acquiring an additional 1,500,000 shares in the last quarter. 72.03% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright increased their price objective on shares of X4 Pharmaceuticals from $3.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.